A role for natural killer cells in the immunopathogenesis of multiple sclerosis

Journal of Neuroimmunology

Volumn 86, Issue 2, 1998, Pages 123-133

  Kastrukoff, Lorne F ^a   Morgan, Norma G ^a   Zecchini, Daniel ^a   White, Richard ^a   Petkau, A John ^a   Satoh, Jun Ichi ^b   Paty, Donald W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

Immunopathogenesis; Multiple sclerosis; Natural killer (NK) cells

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION FUNCTION; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PATHOGENESIS; PRIORITY JOURNAL; TARGET CELL;

ADULT; CHROMIUM RADIOISOTOPES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; RECURRENCE;

EID: 0032526195     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00014-9     Document Type: Article

References (54)

1. Abo T., Balch C.M. A differentiation antigen of human NK cells and K cells identified by a monoclonal antibody (HNK-1). J. Immunol. 127:1981;1024-1029.
2. Abo T., Cooper M.D., Balch C.M. Characterization of HNK-1+ (leu-7) human lymphocytes: 1. two distinct phenotypes of human NK cells with different cytotoxic capability. J. Immunol. 129:1982;1752-1757.
3. Anegon I., Cuturi M.C., Trinchieri G., Perussia B. Interaction of Fc receptor (CD16) with ligands induces transcription of IL-2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J. Exp. Med. 167:1988;452-472.
4. Antel J., Ladiwala U., Qin Y., McCrea E., Becher B. CD56-Dependent cytotoxicity of human oligodendrocytes. Ann. Neurol. 42:1997;422.
5. Benczur M., Pentranyl G.G., Palffy G., Varga M., Talas M., Kotsy B., Foldes I., Hollan S.R. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor. Clin. Exp. Immunol. 39:1980;657-662.
6. Bottino C., Vitale D.P., Biassoni R., Moretta A. Receptors for HLA class I molecules in human NK cells. Semin. Immunol. 7:1995;67-73.
7. Caliguri M.A., Murray C., Levine H., Longtime J.A., Ritz J. Clonal evidence for the induction of NKH on activated humans thymocytes: Functional changes associated with antigen expression. Eur. J. Immunol. 19:1989;1735-1939.
8. Cuturi M.C., Anegon I., Sherman F., Loudon R., Clark S.C., Perussia B., Trinchieri G. Production of hematopoietic colony-stimulating factors by human natural killer cells. J. Exp. Med. 169:1989;569-583.
9. Haahr S., Moller-Larsen A., Pedersen E. Immunological parameters in multiple sclerosis patients with special reference to the herpes virus group. Clin. Exp. Immunol. 51:1983;197-206.
10. Harris J.O., Frank J.A., Patronas N., McFarlin D.E., McFarland H.F. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann. Neurol. 29:1991;548-555.
11. Hauser S.L., Ault K.A., Levin M.J., Garovoy M.R., Weiner H.L. Natural killer cell activity in multiple sclerosis. J. Immunol. 127:1981;1114-1117.
12. Heberman R.R., Ortaldo J.R. Natural killer cells: their role in defense against disease. Science. 214:1981;24-30.
13. Herberman, R.B., 1982. Overview and perspective. Natural resistance mechanism. In: Norman, S. (Ed.), Macrophages and natural killer cells: regulation and function. Plenum, NY, p. 799-808.
14. 2. Clin. Immunol. Immunopathol. 37:1985;236-244.
15. Jondal M., Pross H. Surface markers on human B and T lymphocytes: VI. cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations. Int. J. Cancer. 15:1975;596-605.
16. Kastrukoff L.F., Morgan N.G., Aziz T.M., Zecchini D., Berkowitz J., Paty D.W. Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon. J. Neuroimmunol. 20:1988;15-23.
17. Kermode A.G., Thompson A.J., Tofts P. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain. 113:1990;1477-1489.
18. Knapp W., Rieber P., Daken B. Towards a better definition of human leukocyte surface molecules. Immunol. Today. 10:1989;253-258.
19. Kreuzfelder E., Shen G., Bittorf M., Scheiermann N., Thraenhart O., Seidel D., Grosse-Wilde H. Enumeration of T, B and natural killer peripheral blood cells of patients with multiple sclerosis and controls. Eur. Neurol. 32:1992;190-194.
20. Lanier L.L., Le A.M., Civin C.I. The relationship of CD16 (Leu 11) and Leu 19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 136:1986;4480-4487.
21. Leung K.H., Fischer D.G., Koren H.S. Erythromyeloid tumor cells (K-562) induce PGE synthesis in human peripheral blood monocytes. J. Immunol. 131:1983;445-449.
22. Levy P.C., Shaw G.M., LoBoglio A.F. Human monocyte, lymphocyte and granulocyte antibody dependent cell-mediated cytotoxicity toward tumour cells: I. General characteristics of cytolysis. J. Immunol. 123:1979;594-599.
23. Merrill J., Jondal M., Seeley J., Ullberg M., Siden A. Decreased NK killing in patients with multiple sclerosis: an analysis on the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to the activity of the disease. Clin. Exp. Immunol. 47:1982;419-430.
24. McFarland H.F., Frank J.A., Albert P.S., Smith M.E., Martin R., Harris J.O., Patronas N., Maloni H., McFarlin D.E. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann. Neurol. 32:1992;758-766.
25. Miller D.H., Rudge P., Johnson G. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 111:1988;927-939.
26. Moretta L. Introduction: NK cells: origin, receptors and specificity. Semin. Immunol. 7:1995;57-59.
27. Nagao F., Yabe T., Xu M., Okumura K. Phenotypical and functional analyses of natural killer cells from low NK activity individuals among healthy and patient populations. Nat. Immun. 14:1995;225-233.
28. Nagler A., Lanier L.L., Cwiela S., Phillips J.H. Comparative studies of human FcRIII-positive and negative NK cells. J. Immunol. 143:1989;3183-3189.
29. Neighbour P.A., Grayzel A.I., Miller A.E. Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro: studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis. Clin. Exp. Immunol. 49:1982;11-21.
30. Oger J., Kastrukoff L.F., O'Gorman M., Paty D.W. Progressive multiple sclerosis: abnormal immune factors in-vitro and aberrant correlation with enumeration of lymphocyte subpopulations. J. Neuroimmunol. 12:1986;37-48.
31. Oger J., Kastrukoff L.F., Li D.K.B., Paty D.W. Multiple sclerosis: in relapsing patients, immune functions vary with disease activity as assessed by MRI. Neurology. 38:1989;1739-1744.
32. Perussia B., Starr S., Abraham S., Fanning V., Trinchieri G. Human natural killer cells analyzed by B73.1 monoclonal antibody blocking Fc receptor fractions: I. characterization of lymphocyte subset reactive with B73.1. J. Immunol. 130:1983;2133-2141.
33. Perussia B., Fanning V., Trinchieri G. A human NK and K cell subset shares with cytotoxic T cell expression of the antigen recognized by antibody OKT8. J. Immunol. 131:1983;223-227.
34. Phillips J.H., Lanier L.L. Acquisition of non-MHC restricted cytotoxic function by IL-2 activated thymocytes with an immature antigenic phenotype. J. Immunol. 139:1987;683-690.
35. Phillips J.H., Hori T., Nagler A. Ontogency of human natural killer cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 proteins. J. Exp. Med. 175:1992;1055-1061.
36. Rice G.P.A., Casali P., Merigan T.C., Oldstone M.B.A. Natural killer cell activity in patients with multiple sclerosis given alpha interferon. Ann. Neurol. 14:1983;333-338.
37. Romagnani S. Induction of TH1 and TH2 responses: a key role for the 'natural' immune response? Immunol. Today. 13:1992;379-381.
38. Rumpold H., Kraft D., Obexer G., Bock G., Gebhart W. A monoclonal antibody against a surface antigen shared by human large granular lymphocytes and granulocytes. J. Immunol. 129:1982;1458-1464.
39. Santoli D., Trinchierei G., Moretta L. Spontaneous cell-mediated cytotoxicity in humans: distribution and characterization of the effector cell. Clin. Exp. Immunol. 33:1978;309-318.
40. Santoli D., Hall W., Kastrukoff L.F., Lisak R.P., Perussia B., Trinchieri G., Koprowski H. Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis. J. Immunol. 126:1981;1274-1278.
41. Satoh J., Kim S.U., Kastrukoff L.F. Abscence of natural killer (NK) cell activity against oligodendrocytes in multiple sclerosis. J. Neuroimmunol. 26:1990;75-80.
42. Satoh J., Kim S.U., Kastrukoff L.F. Cytolysis of oligodendrocytes is mediated by killer (K) cells but not by natural killer (NK) cells. J. Neuroimmunol. 31:1991;199-210.
43. Satoh J., Kim S.U., Kastrukoff L.F. Lymphokine-activated killer (LAK) and adherent LAK (A-LAK) activity in multiple sclerosis. J. Neuroimmunol. 32:1991;111-122.
44. Storkus W.J., Salter R.D., Alexander J., Ward F.E., Ruis R.E., Cresswell P., Dawson J.R. Class 1-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2. Proc. Natl. Acad. Sci. U.S.A. 88:1991;5989-5992.
45. Timonen T., Ortaldo J.R., Herberman R.B. Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J. Exp. Med. 153:1981;569-582.
46. Trinchieri G., Perussia B. Biology of disease. Human natural killer cells: biologic and pathologic aspects. Lab. Invest. 50:1984;489-513.
47. Trinchieri G., Matsumoto-Kobayashi M., Clark S.C., Sheehra J., London L., Perussia B. Response of resting human peripheral blood natural killer cells to interleukin-2. J. Exp. Med. 160:1984;1147-1169.
48. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 47:1989;187-376.
49. UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group, Paty D.W., Li D.K.B. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter randomized double-blind, placebo-controlled trial. Neurology. 43:1993;662-667.
50. Van Kessel K.P.M., Verhoef J. A view to kill: cytotoxic mechanisms of human polymorphonuclear leukocytes compared with monocytes and natural killer cells. Pathobiology. 58:1990;249-264.
51. Vervliet G., Claeys H., van Haver H., Carton H., Vermylen C., Meulepas E., Billiau A. Interferon production and natural killer (NK) activity in leukocyte cultures from multiple sclerosis patients. J. Neurol. Sci. 60:1983;137-150.
52. Vranes Z., Poljakovic Z., Marusic M. Natural killer cell number and activity in multiple sclerosis. J. Neurol. Sci. 94:1989;115-123.
53. Warren H.S. NK cell proliferation and inflammation. Immunol. Cell Biol. 74:1996;473-480.
54. Willoughby E.W., Grochowski E., Li nnD.K.B., Oger J., Kastrukoff L.F., Paty D.W. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann. Neurol. 25:1989;43-49.